Study on effectiveness and convalescence prediction factor of the cure for the progress hepatocellular carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1051240060

Enrollment

500

Registered

2024-06-11

Start date

2024-06-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patient who performed radio wave cautery therapy, hepatic artery embolus therapy, hepatic artery intraarterial injection therapy, chemotherapy for a hepatocellular carcinoma on after January 1, 2015

Exclusion criteria

Exclusion criteria: The patient who was able to confirm a declaration of intention of the participation refusal

Design outcomes

Primary

Measure	Time frame
overall survivals	—

Secondary

Measure	Time frame
Tumor shrinkage effect Side effects Blood tests: CBC, prothrombin time, various blood biochemistry (AST, ALT, ALP, gamma-GTP, T-Bil, Alb, Cre, BUN, CRP), tumor markers (AFP(L3), PIVKA-II) Performancs status Progression free survival	—

Contacts

Public ContactNaoki Nishimura

Nara Medical University

na0k1nnn@yahoo.co.jp+81-745-22-3051

Outcome results